Cancer treatment is fraught with uncertainty, both for you and your patients. Now there is a faster, more elegant solution for cell enrichment—ClearCell® FX. Fully automated and entirely label-free, ClearCell® FX empowers doctors through every step of the cancer treatment journey.
Based on the patented microfluidic biochip, CTChip® FR, ClearCell® FX achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer. It even provides the potential for serial real-time treatment monitoring. Clinicians now have a robust and reproducible non-invasive liquid biopsy to monitor metastasis—bringing us closer to providing timely, tailored treatment for patients.
EML4-ALK gene rearrangement in a non-small cell lung cancer (NSCLC) CTC that had been isolated with the ClearCell® FX System and analysed by FISH. Image courtesy of National Cancer Centre, Singapore
Detection of a KRAS mutation in a CTC- enriched sample that had been isolated using the ClearCell® FX System and analysed by Sanger sequencing
Clearbridge BioMedics specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from the National University of Singapore (NUS) and is the first incubatee of Clearbridge Accelerator,a high-technology incubator backed by the Singapore Government’s National Research Foundation.
The ClearCell Systems provide a label-free means of Circulating Tumour Cell (CTC) enrichment, as such, offering a myriad of possibilities for downstream analysis on the output CTCs. Utilising patented award winning microfluidic technologies, Clearbridge BioMedics aims to provide the next generation of non-invasive “liquid biopsy” approaches for cancer screening, diagnosis, staging, personalised medicine and treatment monitoring. Headquartered in Singapore, Clearbridge BioMedics currently has customers across Asia, Europe and North America.